Indoleamine-pyrrole 2,3-dioxygenase might be a prognostic biomarker for patients with renal cell carcinoma.
To explore the role of indoleamine-pyrrole 2,3-dioxygenase (IDO), an immunomodulatory enzyme, in renal cell carcinoma (RCC). A total of 40 patients diagnosed as RCC in the Second Xiangya Hospital were included in this study. All patients received nephrectomy. The histopathological features of samples were assessed semi-quantitatively. IDO mRNA level in RCC and non-RCC renal tissues was determined by real-time quantitative PCR (RT-qPCR). And the expression of IDO protein in endothelial cells was examined by immunohistochemistry; a Kaplan-Meier survival curves was calculated on the basis of IDO mRNA level. Level of IDO mRNA in RCC samples was significantly higher than that in tumor-free samples with P<0.001. Patients with high IDO expression had an significantly longer survival time than those with low IDO expression (P=0.01). There was a statistically significant inverse correlation between IDO and proliferation marker Ki67. Patients with high IDO level were of low Ki67 level, and vice versa (P<0.01). IDO might be a prognostic biomarker for patients with RCC.